From Vision to Action

«To engage SILAB in socially committed action while confirming its scientific culture, fundamental values and humanism – it is for these reasons that I decided on this creation» Jean PAUFIQUE.

The aim of the SILAB - Jean PAUFIQUE Corporate Foundation is to provide active and constant support for Fundamental and applied Research dedicated to the diagnosis, prognosis and treatment of skin pathologies, particularly skin cancer.

Professors Philippe HUMBERT and Christophe BEDANE, opinion leaders in the domain of Dermatological Research, have joined the Governing Body of the Corporate Foundation. They make an essential contribution to the corporate approach based on shared values: a passion for Research and support for young talent.

 

2020 prize-winner: Aïda MEGHRAOUI-KHEDDAR and Solène BESSON

Aïda MEGHRAOUI-KHEDDAR and Solène BESSON were named 13th winners of the SILAB - Jean PAUFIQUE Corporate Foundation.

Aïda MEGHRAOUI-KHEDDAR Aïda MEGHRAOUI-KHEDDAR was awarded for her CARSINO research project “CARcinomes cutanés, Suppression Immunitaire et neuronesNOcicepteurs : vers une nouvelle cible thérapeutique en oncodermatologie/Cutaneous carcinomas, immune suppression and nociceptor neurons: towards a new therapeutic target in oncodermatology”. The studies were conducted at the Institute of Molecular and Cellular Pharmacology, CNRS UMR 7275 and the Université Côte d'Azur in Nice, in the “Regulation of immune responses at muco-cutaneous sites” group, co-directed by Dr. Véronique BRAUD and Dr. Fabienne ANJUERE. The goal of the CARSINO project is to conduct an exhaustive and integrative characterization of the tumor environment of epidermoid cutaneous carcinomas in order to define interactions between nociceptor nerves and suppressive immune cells infiltrating recurrent and inoperable tumors. This will identify predictive biomarkers of these recurrences as well as new therapeutic strategies to stop tumor progression tumorale.

Solène BESSON The research project of Solène BESSON is entitled “Développement de vecteurs d’immunothérapies pour le traitement du mélanome/Development of vectors of immunotherapies for the treatment of melanomas. This work is being done at the Institute of Structural Biology in collaboration with the Établissement Français du Sang/French Blood Institute and the Institute for Advanced Biosciences in Grenoble in the “Adenovirus” and “Immunobiologie et Immunothérapies dans les maladies chroniques/Immunobiology and Immunotherapies in chronic diseases” groups directed by Dr. Pascal FENDER. The research involves the development and preclinical evaluation of new vectors of immunotherapies that stimulate the patient’s immune system to effectively combat melanomas.

___